Monday, 20 Apr 2026
Weather Forecast
  • About Us
  • Contact Us
SUBMIT NEWS
DACH Times™
  • Home
  • Germany
    • Artificial Intelligence
    • Automotive & Mobility
    • Energy
    • Pharmaceuticals
  • Austria
    • Finance
    • Technology
    • Tourism
  • Switzerland
    • FinTech
    • MedTech
    • Pharmaceuticals
  • Europe
  • Press Releases
  • English
    • Français (French)
    • Deutsch (German)
    • Italiano (Italian)
Font ResizerAa
DACH Times™DACH Times™
Search
  • English
    • Français (French)
    • Deutsch (German)
    • Italiano (Italian)
  • Germany
    • Artificial Intelligence
    • Automotive & Mobility
    • Energy
    • Pharmaceuticals
  • Austria
    • Finance
    • Technology
    • Tourism
  • Switzerland
    • FinTech
    • MedTech
    • Pharmaceuticals
  • Europe
  • Press Releases
  • About Us
  • Contact Us
  • Submit News
DACH Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC
DACH Times™ > Blog > Germany > Pharmaceuticals > German Pharma Co. Says Takeda’s ADHD Drug IP Isn’t Valid
Pharmaceuticals

German Pharma Co. Says Takeda’s ADHD Drug IP Isn’t Valid

Last updated: February 28, 2026 9:34 am
Newsroom
Share
SHARE


By Jamie Lennox ( November 12, 2025, 7:47 PM GMT) — The German pharmaceuticals company Aristo has asked a London court to invalidate Takeda’s extended patent protections in the U.K. over the ADHD treatment Elvanse….

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and…



Source link

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Previous Article ‘Minapharm’ inks strategic coop. deal with German pharma giant ‘Bayer’
Next Article Germany and China Signal Upward Market Trajectory

Share DACH Times™!

Your news source on DACH Region
- Advertisement -
Ad image

You Might Also Like

Pharmaceutical Service Provider Vetter Pharma to Build New Manufacturing Site in Germany

By Newsroom

Vetter Pharma to build new manufacturing site in Germany

By Newsroom

How are the US MFN and German MFG likely to impact pharmaceutical companies’ launch strategies?

By Newsroom

Germany and China Signal Upward Market Trajectory

By Newsroom
DACH Times™

About US

DACH Times™ is the definitive multilingual news aggregating platform dedicated to the economic, industrial, and cultural heartbeat of Central Europe that includes Germany (D), Austria (A), and Switzerland (CH). In association with EuropeNewswire.net™, we provide press release in the DACH countries. For more information, contact us through these messaging apps: WhatsApp or Telegram

Categories
  • Austria
  • Germany
  • Switzerland
  • Europe
  • Press Releases
Popular News
The Catalyst of Innovation: How Press Release Distribution Fuels Growth in the DACH Region
April 14, 2026
Multilingual PR in the DACH Region: Benefits of Localized Press Releases
April 10, 2026
The Catalyst Effect: How Press Release Distribution Drives Sicily’s 2026 Economic Pillars
April 1, 2026
Refracting the Spectrum of Business Success: The Essential Role of Strategic Press Release Distribution in Italy and Europe
March 24, 2026
Latest News
High Potency APIs Market Size to Reach USD 49.59 Billion by 2031, Driven by Rising Precision Medicine Demand
April 18, 2026
Home Ventilation System Market to Reach USD 41.12 Billion by 2031, Says Mordor Intelligence
April 18, 2026
$42.6 Billion by 2035 — How AI-Powered Content Intelligence Is Driving Engagement
April 17, 2026
$28.4 Billion by 2035 — How Voice Analytics Is Transforming Contact Center Performance
April 17, 2026
  • English
  • Français (French)
  • Deutsch (German)
  • Italiano (Italian)

DACH Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC

  • About Us
  • Contact Us
  • Submit News
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?